Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2022-11-10 Director's Dealing
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice LL Revised 4 pages 330.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Revised Change of Directors Interest Notice' and includes detailed information about changes in shareholdings and interests of a company director, Lars Lidgren. It references Appendix 3Y, which is a standard form used in Australian stock exchange filings to disclose changes in directors' interests in securities. The content focuses on the director's share transactions and corrections to previously lodged notices. There is no financial performance data, earnings information, or management discussion. The document is not an announcement of a report but a regulatory disclosure about insider share transactions. Therefore, it fits the category of Director's Dealing (DIRS). The document length is sufficient and contains substantive details about the director's share transactions, confirming the classification with high confidence.
2022-11-10 English
Change of Director's Interest Notice LL 3 pages 204.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about changes in a director's relevant interests in securities, including the number of shares held before and after the change, dates, and nature of the transactions. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The content is specific to personal share transactions by a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed transaction data, not just an announcement or certification. Therefore, the correct classification is DIRS with high confidence.
2022-11-08 English
Remplir Gains Australian Reimbursement 3 pages 308.6KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Orthocell Limited's product Remplir™ has been granted inclusion on the Australian Prostheses List, enabling reimbursement by private insurers. It discusses market potential, distributor appointment, clinical study results, and company background. There is no detailed financial data, regulatory filing, or report attached. The content is an update on a capital/financing-related milestone (product reimbursement approval and market entry), which aligns with Capital/Financing Update filings. It is not an annual report, earnings release, or regulatory filing. The document length is moderate and contains substantive information about financing and market access rather than a report or announcement of a report publication.
2022-10-31 English
Appendix 4C - Quarterly 8 pages 456.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report – September 2022' and is dated 31 October 2022. It contains detailed financial and operational information for the quarter ended 30 September 2022, including cash inflows, cash balance, commercial activities, clinical trial updates, and strategic partnerships. The length is substantial (15,000 characters), and it includes substantive financial data and business analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). There is no indication that this is merely an announcement of a report or a certification. Therefore, the document should be classified as an Interim / Quarterly Report (IR).
2022-10-30 English
Results of Meeting 2 pages 146.2KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'RESULTS OF ANNUAL GENERAL MEETING' and provides detailed poll results and proxy votes for resolutions passed at the 2022 Annual General Meeting of Orthocell Limited. It includes voting outcomes on various resolutions such as adoption of the remuneration report, re-election of a director, approval of plans, and placement capacity. The content is focused on the official announcement of voting results from the AGM, not the AGM materials themselves or the full annual report. The document length is about 5,024 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-10-27 English
Investor Presentation 21 pages 6.0MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and contains detailed information about the company's products, strategic partnerships, market positioning, clinical data, and financial highlights. It includes forward-looking statements, corporate snapshots, and product descriptions typical of presentations aimed at investors. There is no indication that this is a regulatory filing, earnings release, or annual report. The length and content are consistent with a detailed investor presentation rather than a brief announcement or certification. Therefore, the document fits the category of an Investor Presentation (IP).
2022-10-25 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.